(Z)-N-[(Z)-ethylideneamino]but-3-en-2-imine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (Z)-N-[(Z)-ethylideneamino]but-3-en-2-imine
• 化学式: C₆H₁₀N₂
• 分子量: 110.16
• InChiKey: HLZIIKPUOFPRAC-SFECMWDFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TYPE PIPÉRIDINE-4-AMINO SUBSTITUÉE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2014102590A1

  公开（公告）日：2014-07-03

  The disclosure relates to Substituted Piperidin-4-amino-Type Compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, Q1, Q2, E1, E2, A, B, D, W, Z, a, b, n, and x are as defined herein, compositions comprising an effective amount of a Substituted Piperidin-4-amino-Type Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Piperidin-4-amino-Type Compound.

  本发明涉及式(I)的取代哌啶-4-氨基型化合物及其药物可接受的盐和溶剂化物，其中R1，R2，R3，Q1，Q2，E1，E2，A，B，D，W，Z，a，b，n和x按本文定义，包含有效量的取代哌啶-4-氨基型化合物的组合物，以及治疗或预防诸如疼痛等症状的方法，包括向需要的动物施用有效量的取代哌啶-4-氨基型化合物。
• [EN] ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS<br/>[FR] COMPOSÉS SE LIANT À L'ASGPR POUR LA DÉGRADATION DE PROTÉINES EXTRACELLULAIRES
  申请人：AVILAR THERAPEUTICS INC

  公开号：WO2021155317A1

  公开（公告）日：2021-08-05

  Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

  描述了将一个与外细胞蛋白结合配体结合的阿斯利康糖蛋白受体（ASGPR）结合配体的化合物和组合物，用于选择性降解体内靶外细胞蛋白以治疗由外细胞蛋白介导的疾病。
• CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20140088099A1

  公开（公告）日：2014-03-27

  Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物，包括PI3激酶活性的化合物，以及与激酶活性相关的疾病和病况的化学化合物、制药组合物和治疗方法，其中包括P13激酶活性。
• TYROSINE KINASE INHIBITORS
  申请人：Principal Biopharma Inc.

  公开号：US20140107151A1

  公开（公告）日：2014-04-17

  The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

  本公开提供的化合物及其药物可接受的盐是酪氨酸激酶抑制剂，特别是BLK、BMX、EGFR、HER2、HER4、ITK、JAK3、TEC、BTK和TXK，因此可用于治疗通过抑制酪氨酸激酶治疗的疾病，如癌症和炎症性疾病，如关节炎等。还提供了含有这些化合物和药物可接受的盐的制药组合物以及制备这些化合物和药物可接受的盐的过程。
• INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK)
  申请人：Dana Farber Cancer Institute, Inc.

  公开号：EP3569598A1

  公开（公告）日：2019-11-20

  The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L1, L2, RA, RC, RD, RE, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases.

  本发明提供了符合式（I）的新型化合物： 其中环 A、环 B、X、L1、L2、RA、RC、RD、RE、m、n 和 p 如本文所定义。本发明的化合物可用于预防和治疗多种与激酶活性相关的人类疾病，例如增殖性疾病、神经退行性疾病、代谢紊乱、炎症性疾病和心血管疾病。